SCHEMBL4564769

SCHEMBL4564769

O=C(O)CNC(=O)c1nc2cc(I)ccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 7/20 0.64
HRH4 Q9H3N8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
IDO1 P14902 1/20 0.38
FAAH O00519 2/20 0.37
HDAC2 Q92769 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
NAMPT P43490 1/20 0.35
CNR2 P34972 1/20 0.35
USP30 Q70CQ3 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
HIF1A Q16665 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
SLC22A8 Q8TCC7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4305878 0.84 EGLN1 (0.81) EGLN1HRH4HRH3KDM4CKDM4E
SCHEMBL12330264 0.83 HRH4 (0.44) EGLN1HRH4HRH3IDO1HDAC2
SCHEMBL4309965 0.81 EGLN1 (0.60) EGLN1HRH4HRH3KDM4CHDAC2
SCHEMBL13625961 0.81 EGLN1 (0.82) EGLN1FAAHKDM4EMAPT
SCHEMBL4307360 0.80 EGLN1 (0.67) EGLN1KDM4CFAAHHDAC2HDAC3
SCHEMBL31024214 0.79 PIN1 (0.53) EGLN1MAPT
SCHEMBL4313112 0.79 EGLN1 (0.57) EGLN1KDM4CFAAHKDM4E
SCHEMBL4309470 0.78 EGLN1 (1.00) EGLN1HRH4HRH3
SCHEMBL2442625 0.78 HRH4 (0.50) HRH4HRH3KDM4EMAPT
SCHEMBL4302354 0.78 EGLN1 (0.56) EGLN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US claimed
WO-2009134754-A1 BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO claimed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
WO-2009134754-A1 BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors EGLN3, EGLN2, P4HA1 EGLN1 5/4885HRH4 1015/4885HRH3 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.